Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03088813
Registration number
NCT03088813
Ethics application status
Date submitted
9/03/2017
Date registered
23/03/2017
Date last updated
17/07/2024
Titles & IDs
Public title
Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer
Query!
Scientific title
RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy
Query!
Secondary ID [1]
0
0
2017-004261-26
Query!
Secondary ID [2]
0
0
MM-398-01-03-04
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
RESILIENT
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Small Cell Lung Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Irinotecan liposome injection
Treatment: Drugs - Topotecan
Experimental: Part 1: Experimental Arm, dose level 1 - Irinotecan liposome injection
Experimental: Part 1: Experimental Arm, dose level 2 - Irinotecan liposome injection
Experimental: Part 2: Experimental Arm - Irinotecan liposome injection
Active comparator: Part 2: Control Arm - Topotecan
Treatment: Drugs: Irinotecan liposome injection
IV
Treatment: Drugs: Topotecan
IV
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)
Query!
Assessment method [1]
0
0
An adverse event (AE) was any untoward medical occurrence in a participant following or during exposure to a study treatment, whether or not causally related to the study treatment. An undesirable medical condition could be symptoms, signs or abnormal results of an investigation. An SAE was any AE that: resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability or incapacity; resulted in congenital anomaly or birth defect; or was medically important. A TEAE was any AE that occurred or worsened on or after the day of first dose of study treatment and within 30 days after discontinuation of study treatment.
Query!
Timepoint [1]
0
0
The TEAEs were reported from the time of first study treatment administration (Day 1) up to 30 days after the date of last study treatment administration, approximately 680 days
Query!
Primary outcome [2]
0
0
Part 1: Number of Participants With Dose-Limiting Toxicities (DLT)
Query!
Assessment method [2]
0
0
A TEAE was considered as DLT if it occurred during the safety evaluation period (i.e. first 28 days of treatment or 14 days after the second dose of study treatment if there was a treatment delay due to non-DLT related reasons) and were deemed related to the study treatment by the investigator. The determination of whether an Adverse Event was considered a Dose Limiting Toxicity was made by the Safety Review Committee (SRC) comprising the Part 1 Investigators and the Medical Monitor(s) of the Sponsor.
Query!
Timepoint [2]
0
0
From the start of the first study treatment administration (Day 1) up to 14 days after the second dose of study treatment administration, a maximum of 42 days
Query!
Primary outcome [3]
0
0
Part 2: Overall Survival (OS)
Query!
Assessment method [3]
0
0
The OS was defined as the time from randomization date to the date of death from any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. The OS was calculated using Kaplan-Meier technique. Following end of treatment participant and/or family was contacted by telephone every month to assess vital status.
Query!
Timepoint [3]
0
0
From date of randomization (within 7 days before start of study treatment) until death. Assessed up to Part 2 primary analysis DCO date of 08 February 2022 (approximately 900 days)
Query!
Secondary outcome [1]
0
0
Part 1: Objective Response Rate (ORR)
Query!
Assessment method [1]
0
0
The ORR was defined as the percentage of participants with a best overall response (BOR) characterized as either a complete response (CR) or partial response (PR) recorded from date of first dose of study treatment until documented PD or death. ORR analysis was based on BOR using RECIST v1.1 per investigator assessment. Per RECIST v1.1, CR is disappearance of all target lesions; PR is \>=30% decrease in the sum of the longest diameter of target lesions; and overall response = CR + PR. Per protocol, participants had computed tomography (CT)-scans and brain magnetic resonance imaging (MRI) every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.
Query!
Timepoint [1]
0
0
RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 1177 days
Query!
Secondary outcome [2]
0
0
Part 1: Progression-Free Survival (PFS)
Query!
Assessment method [2]
0
0
The PFS was defined as time from first dose of study treatment to the first documented objective PD using RECIST v1.1 or death due to any cause, whichever occurs first. Per RECIST 1.1, progression is defined as at least 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The PFS was calculated using Kaplan-Meier technique. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.
Query!
Timepoint [2]
0
0
RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 1177 days
Query!
Secondary outcome [3]
0
0
Part 1: OS
Query!
Assessment method [3]
0
0
The OS was defined as the time from first dose of study treatment to the date of death from any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. The OS was calculated using Kaplan-Meier technique. Following end of treatment participant and/or family was contacted by telephone every month to assess vital status.
Query!
Timepoint [3]
0
0
From Baseline (Day 1) until death. Assessed up to Part 1 DCO date of 11 August 2021 (approximately 1177 days)
Query!
Secondary outcome [4]
0
0
Part 2: PFS
Query!
Assessment method [4]
0
0
The PFS was defined as time from randomization to first documented objective PD using RECIST 1.1 (or response assessment in neuro-oncology brain metastases \[RANO-BM\] criteria for central nervous system \[CNS\] lesions) as assessed by blinded independent central review (BICR) or death due to any cause, whichever occurred first. Per RECIST 1.1, progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The PFS was calculated using Kaplan-Meier technique. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.
Query!
Timepoint [4]
0
0
RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 900 days
Query!
Secondary outcome [5]
0
0
Part 2: ORR
Query!
Assessment method [5]
0
0
The ORR was defined as percentage of participants with a BOR characterized as either a CR or PR, recorded from randomization until documented PD or death relative to the total number of participants. ORR analysis was based on BOR assessed by BICR using RECIST v1.1. Per RECIST v1.1, CR is disappearance of all target lesions; PR is \>=30% decrease in the sum of the longest diameter of target lesions; and overall response = CR + PR. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.
Query!
Timepoint [5]
0
0
RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 900 days
Query!
Secondary outcome [6]
0
0
Part 2: Median Duration of Response (DoR)
Query!
Assessment method [6]
0
0
The DoR was defined as time from the first documented objective response (CR or PR, whichever was earlier) to the date of first documented PD or death due to any cause. The DoR analysis was based on BOR assessed by BICR using RECIST v1.1. Per RECIST v1.1, CR is disappearance of all target lesions and PR is \>=30% decrease in the sum of the longest diameter of target lesions. The DoR was calculated using Kaplan-Meier technique. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.
Query!
Timepoint [6]
0
0
RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 900 days
Query!
Secondary outcome [7]
0
0
Part 2: Median Time to Objective Response (OR)
Query!
Assessment method [7]
0
0
Time to OR as per RECIST v1.1 criteria according to BICR was defined as time from the date of randomization to the date of first documented objective tumor response (CR or PR, whichever was first). Per RECIST v1.1, CR is disappearance of all target lesions; PR is \>=30% decrease in the sum of the longest diameter of target lesion. Participants with a new anti-cancer therapy prior to OR were censored at the last tumor assessment prior to new anti-cancer therapy. Per protocol, participants had CT-scans and brain MRI every 6 weeks to measure tumor lesion size. This was continued throughout treatment until PD or commencement of new anti-neoplastic therapy.
Query!
Timepoint [7]
0
0
RECIST assessments performed at Baseline (within 28 days before start of study treatment), every 6 weeks post first dose and treatment pause, 30 days after discontinuation of study treatment, then every month thereafter, approximately maximum of 900 days
Query!
Secondary outcome [8]
0
0
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)/Lung Cancer Supplement (LC13) Dyspnea Scale at Week 12
Query!
Assessment method [8]
0
0
The EORTC QLQ-LC13 is a lung cancer specific module used in conjunction with EORTC QLQ-C30 and covers typical symptoms of lung cancer (cough, pain, dyspnea, sore mouth, peripheral neuropathy, hair loss). Scores range from 0-100 and a high score represents a high level of symptomatology/problems/worse QoL. Baseline was defined as the last non-missing measurement taken prior to reference start date. Change from baseline in dyspnea scale was calculated regardless of premature study treatment discontinuation. Participants completed these questionnaires on an electronic tablet every 6 weeks during treatment and it was continued until PD or commencement of new anti-neoplastic therapy.
Query!
Timepoint [8]
0
0
Baseline (Day 1) and Week 12
Query!
Secondary outcome [9]
0
0
Change From Baseline in EORTC QLQ-LC13 Cough Scale at Week 12
Query!
Assessment method [9]
0
0
The EORTC QLQ-LC13 is a lung cancer specific module used in conjunction with EORTC QLQ-C30 and covers typical symptoms of lung cancer (cough, pain, dyspnea, sore mouth, peripheral neuropathy, hair loss). Score ranges from 0-100 scale and a high score represents a high level of symptomatology/problems/worse QoL. Baseline was defined as the last non-missing measurement taken prior to reference start date. Change from baseline in cough scale was calculated regardless of premature study treatment discontinuation. Participants completed these questionnaires on an electronic tablet every 6 weeks during treatment and it was continued until PD or commencement of new anti-neoplastic therapy.
Query!
Timepoint [9]
0
0
Baseline (Day 1) and Week 12
Query!
Eligibility
Key inclusion criteria
* At least 18 years of age.
* Able to understand and provide an informed consent
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Life expectancy >12 weeks
* Histopathologically or cytologically confirmed small cell lung cancer
* Evaluable disease as defined by RECIST Version 1.1 guidelines (patients with non measurable lesions only are eligible).
* Radiologically confirmed progression on or after first-line platinum based chemotherapy (carboplatin or cisplatin), or chemo-radiation including platinum-based chemotherapy for treatment of limited or extensive stage Small Cell Lung Cancer (SCLC). In addition to platinum-based regimen, one line of immunotherapy as monotherapy or in combination, in first or in second line setting is allowed.
* Recovered from the effects of any prior chemotherapy, surgery, radiotherapy or other anti-neoplastic therapy (recovered to Grade 1 or better, with the exception of alopecia, peripheral neuropathy, or ototoxicity).
* Adequate bone marrow reserves
* Adequate hepatic function
* Adequate renal function
* Electrocardiogram during the Screening period without any clinically significant findings, per investigator's assessment
* Patients with certain types of asymptomatic CNS metastases that meet ALL the following criteria are eligible.
1. Patients with asymptomatic CNS metastases prior to enrollment
2. Prior radiation for CNS metastatic disease is completed =4 weeks prior to enrollment
3. CNS metastases that are stable or have decreased according to the post radiation follow-up scan that is conducted at least 4 weeks after completion of radiation treatment for CNS lesion.
4. Patients have discontinued corticosteroids or are on stable low-dose steroids (prednisone or equivalent 10 mg daily or less) for at least 1 week after completion of radiation for CNS lesion prior to enrollment.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria
* Any medical or social condition deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results
* Pregnant or breast feeding;
* Patients with large cell neuroendocrine lung carcinoma.
* Patients who have received prior topoisomerase I inhibitor treatment, retreatment with platinum-based regimen, antibody-drug conjugates or molecular targeted agents, more than one line of immunotherapy, or any other additional regimen of prior cytotoxic chemotherapy.
* Patients with the symptomatic Central Nervous System (CNS) metastasis and/or who have developed new or progressive brain metastasis within 3 months following prophylactic and/or therapeutic cranial radiation (whole brain stereotactic radiation).
* Patients with carcinomatous meningitis.
* Unable to discontinue the use of strong CYP3A4 or UGT1A1 inhibitors at least 1 week or strong CYP3A4 inducers at least 2 weeks prior to receiving the first dose of irinotecan liposome injection.
* Have a previous or concurrent cancer that is distinct in primary (non-pulmonary) site or SCLC histology
* Investigational therapy administered within 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is less, prior to the first scheduled day of dosing in this study.
* Severe cardiovascular and pulmonary diseases
* New York Heart Association Class III or IV congestive heart failure, ventricular arrhythmias, or uncontrolled blood pressure.
* Active infection
* Known hypersensitivity to any of the components of irinotecan liposome injection, other liposomal products, or topotecan.
* Clinically significant gastrointestinal disorder including hepatic disorders, bleeding, inflammation, occlusion, or diarrhea > grade 1.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
25/04/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
27/07/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
491
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Border Medical Oncology Research Unit - Albury
Query!
Recruitment hospital [2]
0
0
South West Healthcare - Warrnambool
Query!
Recruitment hospital [3]
0
0
Southern Medical Day Care Centre - Wollongong
Query!
Recruitment hospital [4]
0
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment postcode(s) [1]
0
0
2640 - Albury
Query!
Recruitment postcode(s) [2]
0
0
3280 - Warrnambool
Query!
Recruitment postcode(s) [3]
0
0
- Wollongong
Query!
Recruitment postcode(s) [4]
0
0
- Woolloongabba
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Colorado
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Georgia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Maine
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Maryland
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Michigan
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New York
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Ohio
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Oklahoma
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
South Carolina
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Tennessee
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Washington
Query!
Country [14]
0
0
Belgium
Query!
State/province [14]
0
0
Brasschaat
Query!
Country [15]
0
0
Belgium
Query!
State/province [15]
0
0
Leuven
Query!
Country [16]
0
0
Belgium
Query!
State/province [16]
0
0
Libramont
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Mechelen
Query!
Country [18]
0
0
Brazil
Query!
State/province [18]
0
0
Barretos
Query!
Country [19]
0
0
Brazil
Query!
State/province [19]
0
0
Ijuí
Query!
Country [20]
0
0
Brazil
Query!
State/province [20]
0
0
Nova Lima
Query!
Country [21]
0
0
Brazil
Query!
State/province [21]
0
0
Porto Alegre
Query!
Country [22]
0
0
Brazil
Query!
State/province [22]
0
0
Rio De Janeiro
Query!
Country [23]
0
0
Brazil
Query!
State/province [23]
0
0
Santo André
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
São José Do Rio Preto
Query!
Country [25]
0
0
China
Query!
State/province [25]
0
0
Beijing
Query!
Country [26]
0
0
China
Query!
State/province [26]
0
0
Bengbu
Query!
Country [27]
0
0
China
Query!
State/province [27]
0
0
Changchun
Query!
Country [28]
0
0
China
Query!
State/province [28]
0
0
Chengdu
Query!
Country [29]
0
0
China
Query!
State/province [29]
0
0
Guangzhou
Query!
Country [30]
0
0
China
Query!
State/province [30]
0
0
Hangzhou
Query!
Country [31]
0
0
China
Query!
State/province [31]
0
0
Hubei
Query!
Country [32]
0
0
China
Query!
State/province [32]
0
0
Linyi
Query!
Country [33]
0
0
China
Query!
State/province [33]
0
0
Zhengzhou
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Brest
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Marseille
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Saint-Priest-en-Jarez
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Saint-Quentin
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Freiburg
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Hamm
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Heidelberg
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Oldenburg
Query!
Country [42]
0
0
Hungary
Query!
State/province [42]
0
0
Budapest
Query!
Country [43]
0
0
Hungary
Query!
State/province [43]
0
0
Gyula
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Szolnok
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Törökbálint
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Zalaegerszeg
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Meldola
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
Milano
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Udine
Query!
Country [50]
0
0
Korea, Republic of
Query!
State/province [50]
0
0
Cheongju-si
Query!
Country [51]
0
0
Korea, Republic of
Query!
State/province [51]
0
0
Seoul
Query!
Country [52]
0
0
Korea, Republic of
Query!
State/province [52]
0
0
Suwon
Query!
Country [53]
0
0
Poland
Query!
State/province [53]
0
0
Biala Podlaska
Query!
Country [54]
0
0
Poland
Query!
State/province [54]
0
0
Gdynia
Query!
Country [55]
0
0
Poland
Query!
State/province [55]
0
0
Olsztyn
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Poznan
Query!
Country [57]
0
0
Romania
Query!
State/province [57]
0
0
Bucuresti
Query!
Country [58]
0
0
Romania
Query!
State/province [58]
0
0
Cluj-Napoca
Query!
Country [59]
0
0
Romania
Query!
State/province [59]
0
0
Craiova
Query!
Country [60]
0
0
Romania
Query!
State/province [60]
0
0
Floresti
Query!
Country [61]
0
0
Romania
Query!
State/province [61]
0
0
Timisoara
Query!
Country [62]
0
0
Russian Federation
Query!
State/province [62]
0
0
Arkhangel'sk
Query!
Country [63]
0
0
Russian Federation
Query!
State/province [63]
0
0
Moscow
Query!
Country [64]
0
0
Russian Federation
Query!
State/province [64]
0
0
Omsk
Query!
Country [65]
0
0
Russian Federation
Query!
State/province [65]
0
0
Saint Petersburg
Query!
Country [66]
0
0
Russian Federation
Query!
State/province [66]
0
0
Yaroslavl
Query!
Country [67]
0
0
Serbia
Query!
State/province [67]
0
0
Belgrade
Query!
Country [68]
0
0
Serbia
Query!
State/province [68]
0
0
Belgrad
Query!
Country [69]
0
0
Serbia
Query!
State/province [69]
0
0
Sremska Kamenica
Query!
Country [70]
0
0
Serbia
Query!
State/province [70]
0
0
Užice
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Barcelona
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Alicante
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Madrid
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Málaga
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Sevilla
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Valencia
Query!
Country [77]
0
0
Taiwan
Query!
State/province [77]
0
0
Changhua
Query!
Country [78]
0
0
Taiwan
Query!
State/province [78]
0
0
Kaohsiung
Query!
Country [79]
0
0
Taiwan
Query!
State/province [79]
0
0
Taipei
Query!
Country [80]
0
0
Taiwan
Query!
State/province [80]
0
0
Taoyuan
Query!
Country [81]
0
0
Turkey
Query!
State/province [81]
0
0
Adana
Query!
Country [82]
0
0
Turkey
Query!
State/province [82]
0
0
Edirne
Query!
Country [83]
0
0
Turkey
Query!
State/province [83]
0
0
Istanbul
Query!
Country [84]
0
0
Turkey
Query!
State/province [84]
0
0
Malatya
Query!
Country [85]
0
0
Turkey
Query!
State/province [85]
0
0
Tekirdag
Query!
Country [86]
0
0
Ukraine
Query!
State/province [86]
0
0
Chernivtsi
Query!
Country [87]
0
0
Ukraine
Query!
State/province [87]
0
0
Dnipro
Query!
Country [88]
0
0
Ukraine
Query!
State/province [88]
0
0
Kharkiv
Query!
Country [89]
0
0
Ukraine
Query!
State/province [89]
0
0
Kremenchuk
Query!
Country [90]
0
0
Ukraine
Query!
State/province [90]
0
0
Kryvyi Rih
Query!
Country [91]
0
0
Ukraine
Query!
State/province [91]
0
0
Luts'k
Query!
Country [92]
0
0
Ukraine
Query!
State/province [92]
0
0
Odesa
Query!
Country [93]
0
0
Ukraine
Query!
State/province [93]
0
0
Sumy
Query!
Country [94]
0
0
Ukraine
Query!
State/province [94]
0
0
Uzhgorod
Query!
Country [95]
0
0
Ukraine
Query!
State/province [95]
0
0
Vyshhorod
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Ipsen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A randomized, open label phase 3 study of irinotecan liposome injection (ONIVYDE®) versus topotecan in patients with small cell lung cancer who have progressed on or after platinum-based first-line therapy The study was conducted in two parts: 1. Dose determination of irinotecan liposome injection 2. A randomized, efficacy study of irinotecan liposome injection versus topotecan
Query!
Trial website
https://clinicaltrials.gov/study/NCT03088813
Query!
Trial related presentations / publications
Paz-Ares L, Spigel DR, Chen Y, Jove M, Juan-Vidal O, Rich P, Hayes T, Calderon VG, Caro RB, Navarro A, Dowlati A, Zhang B, Moore Y, Yao X, Kokhreidze J, Ponce S, Bunn PA. RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer. Cancer. 2022 May 1;128(9):1801-1811. doi: 10.1002/cncr.34123. Epub 2022 Feb 23.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Ipsen Medical Director
Query!
Address
0
0
Ipsen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/13/NCT03088813/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/13/NCT03088813/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT03088813
Download to PDF